Anders Tuv
Directeur/Membre du Conseil chez NYKODE THERAPEUTICS
Fortune : - $ au 30/04/2024
Profil
Anders Tuv is currently working as an Investment Director at Radiumhospitalets Forskningsstiftelse.
He is also serving as a Director at Nykode Therapeutics ASA, Nextera AS, Zelluna Immunotherapy AS, Nucligen AS, and Artbio AS.
In addition, he holds the position of Investment Director at Radforsk since 2011.
Mr. Tuv has previously worked as the Chairman of OncoImmunity AS and as a Director at Oslo Cancer Cluster NCE.
He has also served as an Independent Director at Photocure ASA and as a Managing Consultant at Ernst & Young AS.
Mr. Tuv completed his graduate degree at BI Norwegian Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NYKODE THERAPEUTICS ASA
-.--% | 25/01/2023 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Anders Tuv
| Sociétés | Poste | Début |
|---|---|---|
| NYKODE THERAPEUTICS | Directeur/Membre du Conseil | 22/12/2021 |
Nextera AS
 Nextera AS Miscellaneous Commercial ServicesCommercial Services Nextera AS provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer. It offers platform for protein engineering and evolution, such as life sciences, drug discovery, and lead optimization fields. The firm’s core competence lies within protein engineering and evolution utilizing its technology to epitope discovery and epitope validation, as well as lead-candidate generation and validation in-vitro. The company was founded by Geir Åge Løset and Inger Sandlie in 2009 and is headquartered in Oslo, Norway. | Directeur/Membre du Conseil | 01/01/2012 |
Radiumhospitalets Forskningsstiftelse
 Radiumhospitalets Forskningsstiftelse Financial ConglomeratesFinance Radiumhospitalets Forskningsstiftelse invests in companies from Nordic research institutions. It is a pre-seed investor and project developer focused on cancer. It strengthens cancer research at Rikshospitalet University Hospital, including The Norwegian Radium Hospital. It provides Oslo Cancer Cluster with the necessary infrastructure and management team, as well. The company was founded in 1986 and is headquartered in Lysaker, Norway. | Directeur en chef des Investissements | - |
Zelluna Immunotherapy AS
 Zelluna Immunotherapy AS BiotechnologyHealth Technology Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway. | Directeur/Membre du Conseil | - |
| Radforsk | Directeur en chef des Investissements | 01/01/2011 |
| Nucligen AS | Directeur/Membre du Conseil | - |
Artbio AS
 Artbio AS BiotechnologyHealth Technology Part of Artbio, Inc., Artbio AS is a clinical-stage radiopharmaceutical biotechnology business that works to create a new class of alpha radio ligand medicines. The company is based in Oslo, Norway. The Norwegian company was founded in 2018. The CEO is Emanuele Ostuni. | Directeur/Membre du Conseil | - |
Anciens postes connus de Anders Tuv
| Sociétés | Poste | Fin |
|---|---|---|
| PHOTOCURE ASA | Directeur/Membre du Conseil | - |
Ernst & Young AS
 Ernst & Young AS Miscellaneous Commercial ServicesCommercial Services Part of Ernst & Young Global Ltd., Ernst & Young AS is a Norwegian company that provides accounting services. The company is based in Oslo, Norway. The CEO of the company is Christin Erichsen Bøsterud. | Corporate Officer/Principal | - |
| ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░ | - |
| ░░░░ ░░░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Anders Tuv
| BI Norwegian Business School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PHOTOCURE ASA | Health Technology |
| NYKODE THERAPEUTICS | Health Technology |
| Entreprise privées | 9 |
|---|---|
Oslo Cancer Cluster NCE
 Oslo Cancer Cluster NCE Miscellaneous Commercial ServicesCommercial Services Oslo Cancer Cluster NCE is an oncology research firm that specializes in developing cancer diagnostics and medicines. The private company is based in Oslo, Norway. | Commercial Services |
Radiumhospitalets Forskningsstiftelse
Radiumhospitalets Forskningsstiftelse Financial ConglomeratesFinance Radiumhospitalets Forskningsstiftelse invests in companies from Nordic research institutions. It is a pre-seed investor and project developer focused on cancer. It strengthens cancer research at Rikshospitalet University Hospital, including The Norwegian Radium Hospital. It provides Oslo Cancer Cluster with the necessary infrastructure and management team, as well. The company was founded in 1986 and is headquartered in Lysaker, Norway. | Finance |
Ernst & Young AS
Ernst & Young AS Miscellaneous Commercial ServicesCommercial Services Part of Ernst & Young Global Ltd., Ernst & Young AS is a Norwegian company that provides accounting services. The company is based in Oslo, Norway. The CEO of the company is Christin Erichsen Bøsterud. | Commercial Services |
Nextera AS
Nextera AS Miscellaneous Commercial ServicesCommercial Services Nextera AS provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer. It offers platform for protein engineering and evolution, such as life sciences, drug discovery, and lead optimization fields. The firm’s core competence lies within protein engineering and evolution utilizing its technology to epitope discovery and epitope validation, as well as lead-candidate generation and validation in-vitro. The company was founded by Geir Åge Løset and Inger Sandlie in 2009 and is headquartered in Oslo, Norway. | Commercial Services |
Zelluna Immunotherapy AS
Zelluna Immunotherapy AS BiotechnologyHealth Technology Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway. | Health Technology |
OncoImmunity AS
 OncoImmunity AS Packaged SoftwareTechnology Services OncoImmunity AS develops software solutions that facilitate patient selection for cancer immunotherapy. It offers proprietary machine-learning based software to address the key knowledge gaps in the prediction of bone fide immunogenic neoantigens for personalized cancer immunotherapy. The company was founded by Richard Stratford and Trevor Clancy in 2014 and is headquartered in Oslo, Norway. | Technology Services |
| Nucligen AS | |
| Radforsk | |
Artbio AS
Artbio AS BiotechnologyHealth Technology Part of Artbio, Inc., Artbio AS is a clinical-stage radiopharmaceutical biotechnology business that works to create a new class of alpha radio ligand medicines. The company is based in Oslo, Norway. The Norwegian company was founded in 2018. The CEO is Emanuele Ostuni. | Health Technology |
